
Roche withdraws Tecentriq combo application in first-line renal cell carcinoma
pharmafile | November 19, 2018 | News story | Sales and Marketing | Cancer, Roche, avastin, pharma, renal cell carcinoma, tecentriq
The EMA has revealed that Roche has chosen to withdraw its marketing application for immunotherapy Tecentriq (atezolizumab) in combination with Genentech’s Avastin (bevacizumab) as a first-line treatment for renal cell carcinoma (RCC) due to insufficient data.
Specifically, Roche pulled the application because study findings on the drug combo’s efficacy “are not sufficient to support an extension of indication at this time,” it said. The company was seeking approval for the Tecentriq combination in the treatment of locally advanced of metastatic RCC in tumours with a PD-L1 expression of at least 1%.
Data submitted with the original application demonstrated that Tecentriq plus Avastin reduced the risk of disease progression or death by 26% compared to Pfizer’s Sutent (sunitinib) when used in the first-line against advanced or metastatic RCC. However, overall survival data was too immature at the time of submission, though Roche called them “encouraging”, and
Roche’s decision comes just before the agency’s expert panel, the Committee for Medicinal Products for Human Use (CHMP), was able to come to a recommendation on whether to approve the combo.
“We are waiting for the data to mature,” said the company. “We believe that the combination of Tecentriq and Avastin may play a role in the treatment of metastatic RCC [which] remains an area of high unmet medical need.”
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds

Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …






